TERMS OF PARTICIPATION

1. INTRODUCTION
   The NovoCare™ Patient Support Program (PSP) ("NovoCare™") is a patient support program for patients with diabetes and/or obesity ("Program"), that has been developed by Novo Nordisk Pharmaceuticals (Philippines), Inc. with office address at 21F, Twenty-Four Seven McKinley Building, 24th Street corner 7th Avenue, Bonifacio Global City, Fort Bonifacio, Taguig City ("Novo Nordisk"). Novo Nordisk has contracted GLOBO ASIATICO ENTERPRISES INC, with office address at 127 JDK Bldg,.Maginhawa St. Teachers Village-East Quezon City (“GLOBO”) to implement this program. This PSP provides information and support to patients living with diabetes and/or obesity, to whom Novo Nordisk product/s has been prescribed. This program involves processing of personal and health information; please read the Notice of Data Processing below.
   
   All services provided by Novo Nordisk and/or GLOBO, within the scope of NovoCare™ PSP are subject to the Terms of Participation set forth herein. Novo Nordisk reserves the right to change these Terms of Participation from time to time. For material changes that may affect participants’ rights or obligations, Novo Nordisk will inform all registered participants at least one (1) month in advance. For non-material changes (including those driven by logistics, operational adjustments, contact details/hotline updates, or system/vendor changes) or where required to meet legal, regulatory, or patient safety requirements, Novo Nordisk may provide notice as soon as reasonably practicable.
   
   All Novo Nordisk medicinal products are available by prescription only. Accordingly, only patients who have been prescribed a Novo Nordisk product by their treating physician are eligible to enroll in NovoCare™ PSP. The Program is intended solely for the enrolled patient, and you must not share, transfer, or grant access to NovoCare™ PSP (including any program communications, links, or materials) to any other person.
   
   
2. REGISTRATION
   If you would like to participate in NovoCare™ PSP, your prescribing doctor may complete the HCP registration form with you and submit it to Globo. Alternatively, you may enroll by completing the patient registration form and submitting it to NovoCare™ PSP via Globo’s database, SMS messaging, phone call or email using the contact details provided in Section 8 (Contact Information) of these Terms of Participation.
   
   As set forth above, only patients with diabetes and/or obesity and who have been prescribed Novo Nordisk product by their doctor are eligible to participate in NovoCare™ PSP. By registering for NovoCare™ PSP, you confirm that your doctor has prescribed a Novo Nordisk product to you. Novo Nordisk reserves the right to reject your registration or to terminate your participation in NovoCare™ PSP if Novo Nordisk determines that you do not meet the foregoing eligibility criteria
   
   
3. PERSONAL DATA
   When you register for NovoCare™ PSP, you will be asked to submit certain personal data, including health data. Please read our terms of participation and if you agree to the processing and use by Novo Nordisk of your personal data for the purposes specified therein, we request you to sign the consent declaration. You may withdraw your consent at any time by contacting Novo Nordisk using the details in the Notice of Data Processing below. If you withdraw your consent, NovoCare™ PSP services (including reminders and coaching calls, where applicable) will be discontinued and we will stop processing your personal data for PSP purposes going forward. This will not affect the lawfulness of processing carried out prior to the withdrawal of your consent
   
   If you participate in NovoCare™ PSP, the following services may be available to you:
   
   • Reminder SMS service: Two versions of SMS/chat Reminders will be available, intended to help you to start and maintain daily routines favorable for managing your disease: basic treatment reminders and advanced SMS reminders configurable on the website and also by calling the hotline number.
   • Invitation to access or utilize disease awareness or treatment related digital solutions such as mobile app, websites which are designed to support patient’s health journey.
   • Topic SMS/Chat or email: You will receive personalized information by SMS or email intended to help you stay motivated, e.g. regarding a healthy lifestyle and healthy eating.
   • Calls from specially trained coaches: Upon your needs, up to 4 calls (1 welcome call, 2 follow-up calls and 1 exit call) can be scheduled during the program. During each call, next call appointment will be scheduled with the coach upon your availability.
   • The welcome call is aimed at introducing you to the program and sets expectations for the coming weeks. It will also give you the opportunity to take the profiling questionnaire and configure your program.
   • The 2 follow-up calls are aiming to support your progress on your treatment, answer the questions you may have, offer advice on how to manage your diabetes and stay on track with your medicine. It will also remind you for your next doctor’s appointment, how to make the most of it. The 1-month survey will be proposed.
   • The exit call is aiming to help you reflect on your journey with a new injectable treatment, communicate on ending the PSP and prepare you for after the 120 days. The 4-month survey will also be proposed to you.
   
   
4. CHANGES
   Novo Nordisk reserves the right to modify, reduce, suspend, or discontinue any of the services under NovoCare™ PSP at any time. Where reasonably practicable, Novo Nordisk will provide prior notice to registered participants; however, changes may take effect immediately where required for operational, legal, regulatory, or patient safety reasons.
   
   
5. LIABILITY
   The use of services provided under NovoCare™ PSP is at your own discretion and risk. You remain solely responsible for any medical decisions you make, including decisions relating to your diagnosis, treatment, and medication use. Any information or support provided through NovoCare™ PSP is for general support purposes only and does not constitute, and is not a substitute for, medical advice, diagnosis, or treatment. Please consult your treating physician for medical advice and before making any changes to your treatment, and contact your doctor promptly if you have questions regarding your condition or care.
   
   
6. TERMINATION
   You may at any time terminate your participation in NovoCare™ PSP by notifying Novo Nordisk in writing (by postal mail, fax/telefax or email) using the contact details set out in Section 8 (Contact Information) of these Terms of Participation.
   
   As set forth in section 1 above, you are not allowed to grant access to NovoCare™ PSP to third persons for legal reasons. Novo Nordisk reserves the right to terminate your participation in NovoCare™ PSP, if you breach this requirement.
   
   
7. CONTACT INFORMATION
   Any communication to Novo Nordisk regarding NovoCare™ PSP should be addressed as follows:
   
   GLOBO ASIATICO ENTERPRISES INC
   Number: 0917-686-2273
   Email: novocarepsp@globoasiatico.com
   Address: 127 JDK BLDG MAGINHAWA ST. TEACHERS VILLAGE-EAST 1101 QUEZON CITY Philippines
   
   
8. SEVERABILITY CLAUSE
   Should any provision of these Terms of Participation be or become invalid or unenforceable as a whole or in part, the validity and enforceability of the remaining provisions shall not be affected thereby.
   
   
9. GOVERNING LAW
   The provisions of these Terms of Participation are subject to the laws of the Philippines
   

Would you like to proceed with your enrollment?

NOTICE OF DATA PROCESSING and CONSENT TO DATA PROCESSING

Dear Patient,

You are interested in participating in NovoCare™ PSP, a patient support program for patients with diabetes and/or obesity/rare disease ("Program"), developed by Novo Nordisk Pharmaceuticals (Philippines), Inc. with office address at 21F, Twenty-Four Seven McKinley Building, 24th Street corner 7th Avenue, Bonifacio Global City, Fort Bonifacio, Taguig City ("Novo Nordisk"). Novo Nordisk has engaged GLOBO ASIATICO ENTERPRISES INC with office address at 127 JDK Bldg, Maginhawa St. Teachers Village-East Quezon City (“GLOBO”) to support the implementation of this program. This PSP provides information and support to patients living with diabetes/obesity, to whom Novo Nordisk product/s has been prescribed.

When you register for NovoCare™ PSP, you will be asked to provide certain personal data, including health data, which will be processed (e.g., collected, used, stored, and disclosed/shared where necessary) for the purposes of administering and delivering the Program, as described below. Novo Nordisk will process your personal data for Program purposes only where you have provided your consent as described in this Notice and the consent declaration below. If you do not provide your consent, you will not be able to participate in NovoCare™ PSP.

Therefore, please read the following information thoroughly and talk to your doctor or call the NovoCare™ PSP hotline, if you have any questions. If you agree to the processing of your personal data by Novo Nordisk, we request you to sign the consent declaration below.

Please note that only patients living with diabetes/obesity, to whom Novo Nordisk product/s has been prescribed by their doctor, are eligible to participate in NovoCare™ PSP. When you register for NovoCare™ PSP, you confirm that your doctor has prescribed Novo Nordisk product/s to you.

1. Personal Data
   If you would like to register for NovoCare™ PSP you will be asked to submit your following personal data:
   • Name
   • Birth Year
   • City
   • Gender
   • Phone Number and Email Address
   • Diagnosis
   • Information about the onset of the disease and duration of your treatment with NN product
   
   
2. Purpose of Data Processing
   Novo Nordisk will process the personal data we collect directly from you as follows:
   
   (a) Your personal data is used by Novo Nordisk for PSP delivery (enrollment, reminders, coaching, support), program improvement (surveys; anonymized analytics), and PV safety reporting
   • We ask for your city so we can connect you with the appropriate educator/coach assigned to your area.
   • We use your mobile number and email address only for the services you choose, such as:
     - sending reminders (SMS/chat),
     - sending helpful program updates by SMS or email, and/or
     - arranging calls with specially trained coaches
   • We use the treatment‑related information you provide to tailor the support and content you receive and to help our coaches better understand your needs during program interactions.
   • We may collect your information through electronic or paper forms, and through program communications (e.g., SMS/chat, email, or phone calls) when you enroll or interact with NovoCare™ PSP. We will use and share your information only as needed to administer and deliver the Program (for example, to register you, provide the services you choose, and support quality and safety requirements).
   
   (b). You will be asked to complete a questionnaire regarding your treatment adherence and satisfaction with NovoCare™ PSP at the end of the first month of the program and at the end of the program, through the website or with a care coach over the phone. Your participation in the questionnaire is not required for your participation in the program. The purpose of this questionnaire is for Novo Nordisk to consider the information you provide for further improvements of the program.
   
   Novo Nordisk may use all information collected in the context of NovoCare™ PSP for anonymous statistical evaluation and for further development of the services. Possible results of this evaluation, which will not contain any personal reference or link to your identity, may be published or shared with other companies or contractors of the Novo Nordisk group worldwide.
   
   Data Controller
   The company responsible for processing your personal data is:
   
   Novo Nordisk Pharmaceuticals (Philippines), Inc.
   21F, Twenty-Four Seven McKinley Building,
   24th Street corner 7th Avenue, Bonifacio Global City, Fort Bonifacio, Taguig City
   Tel.: +63 82343500
   E-mail: privacyph@novonordisk.com
   
   Globo Asiatico Enterprices, Inc.
   127 JDK Bldg,.Maginhawa St. Teachers Village-East Quezon City
   Tel.: 02 89827089
   Email: dataprivacy@globoasiatico.com
   
   You can always contact Novo Nordisk or the Novo Nordisk Data Privacy Officer at privacyph@novonordisk.com with questions or concerns about how we process your personal data.
   
   
3. Processors of your Data
   Novo Nordisk may share your personal data with service providers that support NovoCare™ PSP, who process data only on Novo Nordisk’s instructions and only for Program purposes.
   
   Novo Nordisk has appointed Globo Asiatico Enterprises Inc. with office address at 127 JDK Bldg. Maginhawa St. Teachers Village-East Quezon City (“GLOBO”) with the development of the NovoCare™ PSP platform and with support and maintenance services related.
   
   Novo Nordisk has engaged GLOBO ASIATICO ENTERPRISES INC., 127 JDK Bldg., Maginhawa St., Teachers Village‑East, Quezon City, to support the delivery of NovoCare™ PSP (e.g., programme onboarding/support, contact centre and coaching interactions, and related communications with patients and HCPs). In performing these services, authorized GLOBO personnel may access identifiable information (such as your name and contact details) and health information you provide only to the extent necessary to deliver the Program services you choose.
   
   For any concerns, please contact the following:
   Entity name: Globo Asiatico Enterprises Inc
   Tel.: 02 89827089
   Email: dataprivacy@globoasiatico.com
   127 JDK Bldg,.Maginhawa St. Teachers Village-East Quezon City
   
   
4. Transfer of Personal Data
   Your personal data will not be transferred to recipients outside of the Philippines. However, Safety Information (Section 9) and related personal data may be transferred to Novo Nordisk’s global safety database and shared with relevant health authorities and Novo Nordisk entities/partners as required by law.
   
   
5. Information Right and Right to Rectification
   You are entitled to request information from Novo Nordisk about your personal data processed in the context of NovoCare™ PSP. Novo Nordisk will provide a copy of the personal data undergoing processing at your request. If the data should be inaccurate or incomplete, you can ask for your data to be rectified or completed. If the accuracy of your data should be contested, you are entitled to ask for the processing of your data to be restricted for a period enabling Novo Nordisk to verify the accuracy of the data.
   
   
6. Deletion of Data
   Novo Nordisk will store your personal data for the duration of the NovoCare™ PSP program and for a period of three years beyond its termination. You may at any time during the aforesaid period request deletion of your personal data by Novo Nordisk by notifying Novo Nordisk of your request, and Novo Nordisk will initiate deletion of your personal data, including all back-up copies, without undue delay.
   
   If you opt in to receiving SMS services or reminders, Globo will store your mobile number for a period of three years beyond termination of the NovoCare™ PSP.
   
   
7. Data Portability
   At your request, Novo Nordisk will make available your personal data in a structured and machine- readable format to you or to a third party, of your choice.
   
   
8. Right of Revocation
   You are entitled to revoke (withdraw) any consent given, in whole or in part, regarding the processing and use of your personal data for NovoCare™ PSP.
   
   If you revoke your consent, Novo Nordisk (and its processors) will stop processing your personal data for NovoCare™ PSP purposes going forward, and your participation in NovoCare™ PSP (and the related services) will end. The revocation of your consent does not affect the lawfulness of processing carried out before your consent was revoked.
   
   However, Safety Information (Section 9) and related personal data may still be processed and may be transferred to Novo Nordisk’s global safety database and shared with relevant health authorities and Novo Nordisk entities/partners as required by law (e.g., for pharmacovigilance and patient safety obligations.
   
   
9. Safety Information
   In accordance with applicable laws and in the event that you report Safety Information, Novo Nordisk and/or Globo will (i) report Personal Data related to Safety Information to Novo Nordisk, (ii) enter the Safety Information in Novo Nordisk’s global safety database, analyze and regularly assess to identify overall patterns, (ii) share Personal Data related to Safety Information with health authorities, other Novo Nordisk entities, partner companies that assist Novo Nordisk and other pharmaceutical companies if the safety information is considered related to their products, and (iv) Personal Data related to Safety Information will be kept permanently by Novo Nordisk.
   
   Safety Information are all reports of adverse events occurring during the use of a Novo Nordisk drug product or a medical device.

Consent to Processing of Personal Data

I have understood the above information and I explicitly consent to the processing of my personal data submitted in the context of NovoCare™ PSP by Novo Nordisk for the purpose set forth in section 2 (a) above.

I also consent to the use by Novo Nordisk of any information I provide in response to the questionnaires submitted to me at the end of the first month and at the end of the programme for the purpose of further improving the programme, as set forth in section 2 (b) above.

---

ANNEX A – OPTIONAL CONSENT FOR RESEARCH / REAL‑WORLD EVIDENCE (RWE)

Purpose: This Annex applies only if you choose to opt in to the optional research / evidence‑generation purpose described below. Your decision will not affect your participation in, or access to, NovoCare™ PSP services.

Research / Real‑World Evidence (RWE) (separate from NovoCare™ PSP services)

If you tick this box, you agree that Novo Nordisk may use information collected about you through NovoCare™ PSP to create anonymized and aggregated datasets (meaning results do not identify you) together with data from other participants, for research or evidence‑generation purposes, such as understanding patient experiences and outcomes in real‑world settings (outside clinical trials). Any such activity will be conducted under appropriate internal governance and approvals, and any results will be shared only in anonymized/aggregated form.

No impact if you do not opt in: If you do not tick this box, you can still participate fully in NovoCare™ PSP, and you will continue to receive the Program services you choose.

Enter cellphone number:
+63
We will send the OTP to your number to verify your enrollment.

Patient Enrollment Details:
Last Name
Middle Name
First Name
Contact Number
Email Address
Gender	Male Female
Birth Year
City
Diagnosis
Year of Diagnosis
I would like to receive updates and feedback from NovoCare™ PSP	Yes No
OTP (Resend)

Patient Enrollment Details (PREVIEW):
Last Name
Middle Name
First Name
Contact Number
Email Address
Gender
Birth Year
City
Diagnosis
Year of Diagnosis
I would like to receive updates and feedback from NovoCare™ PSP
OPTIONAL CONSENT FOR RESEARCH / REAL‑WORLD EVIDENCE (RWE)

Thank you for completing the form!

Our team will reach out to you within one (1) business day to assist with your next steps.